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Background: Gait disturbance is an early, cardinal feature of Parkinson’s disease (PD)
associated with falls and reduced physical activity. Progression of gait impairment in
Parkinson’s disease is not well characterized and a better understanding is imperative
to mitigate impairment. Subtle gait impairments progress in early disease despite
optimal dopaminergic medication. Evaluating gait disturbances over longer periods,
accounting for typical aging and dopaminergic medication changes, will enable a better
understanding of gait changes and inform targeted therapies for early disease. This study
aimed to describe gait progression over the first 6 years of PD by delineating changes
associated with aging, medication, and pathology.
Methods: One-hundred and nine newly diagnosed PD participants and 130 controls
completed at least two gait assessments. Gait was assessed at 18-month intervals for
up to 6 years using an instrumented walkway to measure sixteen spatiotemporal gait
characteristics. Linear mixed-effects models assessed progression.
Results: Ten gait characteristics significantly progressed in PD, with changes in four
of these characteristics attributable to disease progression. Age-related changes also
contributed to gait progression; changes in another two characteristics reflected both
aging and disease progression. Gait impairment progressed irrespective of dopaminergic
medication change for all characteristics except step width variability.
Conclusions: Discrete gait impairments continue to progress in PD over 6 years,
reflecting a combination of, and potential interaction between, disease-specific
progression and age-related change. Gait changes were mostly unrelated to
dopaminergic medication adjustments, highlighting limitations of current dopaminergic
therapy and the need to improve interventions targeting gait decline.
Keywords: gait, walking, Parkinson’s disease, neurological disorders, aging, longitudinal
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INTRODUCTION
Gait impairment is a common and debilitating feature of
Parkinson’s disease (PD) which manifests in the early and even
prodromal disease stages (Galna et al., 2015; Del Din et al.,
2019a). It impacts independence and quality of life (Curtze
et al., 2016) and is associated with an increased falls risk (Lord
et al., 2016) and reduced physical activity levels (Lord et al.,
2013c; Del Din et al., 2019b). Dopaminergic medication can
provide immediate improvements in some characteristics of PD
gait including walking speed (Bryant et al., 2011; Sterling et al.,
2015). However, other characteristics such as gait variability
continue to worsen over time despite optimal dopaminergic
treatment (Galna et al., 2015). This suggests that additional
interventions are required to mitigate against gait impairment
and its progression (Lord et al., 2011) to reduce falls and increase
physical activity.
Developing successful interventions is made difficult by
the multifaceted etiology of gait impairment in PD. Gait
impairment is underpinned by a complex interaction of
pathology, age-related changes, compensatory mechanisms
and, eventually, secondary deconditioning due to restricted
mobility (Lord et al., 2013a). This explains, in part, the
highly variable response to dopaminergic medication. Teasing
apart changes in gait due to aging, PD, and medication is a
fundamental step towards developing therapies that minimize
gait impairment.
Previous work (Rochester et al., 2017) showed that discrete
gait characteristics (variability of step time, step length, and
step width) progress more rapidly over 3 years in a newly
diagnosed, optimally medicated PD cohort than in age-matched
controls. This provided the first evidence suggesting that the
progression rate is driven by several factors related to age and
pathology. Other studies have identified a shortening of step
length and swing time over 18 months from PD diagnosis
(Galna et al., 2015) and greater increases in step or stride
time variability over 5 years in early and moderate stages of
PD compared to healthy controls (Hobert et al., 2019; Micó-
Amigo et al., 2019). However, relatively short study timeframes,
inconsistent reporting of gait characteristics, lack of control
cohorts, limited exploration of medication effects, and wide
variation in disease duration at inclusion have limited insights
into progression, particularly concerning background aging
and medication.
To comprehensively determine the changes in gait
which are specifically due to PD progression, gait change
should be modeled over a longer timeframe concerning
an age-matched control cohort and with consideration of
changes in dopaminergic medication. Additionally, modeling
gait progression from diagnosis enables a more precise
understanding of gait changes occurring before the onset of
more severe motor symptoms and, therefore, during a time
when interventions may be most beneficial.
The aims of this study were therefore to: (i) identify
gait characteristics that significantly changed over 6 years
in newly diagnosed PD and healthy age-matched controls;
(ii) evaluate gait changes in the PD cohort which related
to aging and disease progression by comparing rates
of gait change between PD and control groups; and
(iii) explore the relationship between gait changes and
changes in dopaminergic medication dose in early PD. It was
hypothesized that:
(1) Variability of step time, step length, and step width will
significantly change over the first 6 years of PD, as they did
over the first 3 years (Rochester et al., 2017).
(2) Additional characteristics to those already identified in
our earlier work (Rochester et al., 2017) will demonstrate
significant change over 6 years that are specific to the
PD cohort, to reflect the additional progression of PD
pathology over a longer timeframe as well as any potential
contributions of compensatory mechanisms and secondary
deconditioning due to restricted mobility.
(3) Change in selective gait characteristics such as step
length will be associated with changes in dopaminergic
medication, as have been identified previously (Rochester
et al., 2017), to indicate dopa-responsive and dopa-resistant
gait characteristics.
To address these hypotheses, we have extended on our
previous 36-month longitudinal analysis of gait in an incident
cohort of people with PD (tested ‘‘on’’ their medication) and
age-matched controls (Rochester et al., 2017), to now include
more recent data from 54 and 72 months follow up assessments.
MATERIALS AND METHODS
Participants
Participants with newly diagnosed idiopathic PD were recruited
into ICICLE-GAIT, a study nested within the ICICLE-PD
study (Incidence of Cognitive Impairment in Cohorts with
Longitudinal Evaluation—PD). Recruitment was conducted
between June 2009 and December 2011, as described fully
in previous publications (Khoo et al., 2013; Lord et al.,
2014; Yarnall et al., 2014). Briefly, people with PD had to
be diagnosed (and confirmed at each follow-up assessment)
with idiopathic PD according to the UK Parkinson’s Disease
Brain Bank criteria by a movement disorders specialist and were
excluded if they presented with significant memory impairment
[Mini-Mental State Exam (MMSE) <24], dementia with Lewy
bodies, drug-induced parkinsonism, ‘‘vascular’’ parkinsonism,
progressive supranuclear palsy, multiple system atrophy,
cortico-basal degeneration or poor command of English.
Potential participants were excluded if they presented with any
neurological (other than PD), orthopedic, or cardiothoracic
conditions that may have severely affected their walking or safety
during the testing sessions. Also, control participants had to
be at least 60 years of age, able to walk independently without
a walking aid, and have no significant cognitive impairment,
mood, or movement disorder.
Assessments were completed every 18-months from baseline
recruitment up to 72-months after baseline. Participant
recruitment and attrition are displayed in Figure 1. The present
analyses included an additional participant compared to previous
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FIGURE 1 | Flow chart indicating participant recruitment and attrition throughout the ICICLE-GAIT study. Some participants were readmitted into the study having
previously withdrawn due to acute pain or illness.
work from the ICICLE-GAIT study (Rochester et al., 2017),
due to the participant re-entering the study at the 54-month
assessment following acute orthopedic issues. PD participants
were tested ‘‘on’’ medication, defined as 1 h after PD medication.
Age-matched controls were recruited from the community to
evaluate changes due to typical aging. The study was approved by
the Newcastle and North Tyneside Research Ethics Committee
and participants gave written informed consent.
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Gait Assessment
Participants walked at their self-selected pace for 2 min
around a 25-m oval circuit which included a 7-m long
instrumented walkway (240 Hz sampling frequency, Platinum
model GAITRite, software version 4.5, CIR Systems, USA).
At least 40 steps were completed over the walkway per
participant to ensure robust measurement of gait variability
(Galna et al., 2013). Gait outcomes were derived and quantified
according to an a priori model developed for older adults
(Lord et al., 2013b), and validated in PD (Lord et al.,
2013a), that describes 16 discrete gait characteristics within
five domains (Pace; Variability; Rhythm; Asymmetry; and
Postural control—see Table 2 for a list of characteristics; Galna
et al., 2015). Methods to calculate the gait characteristics have
been detailed previously (Galna et al., 2013) but are briefly
detailed here:
Step length: distance in the direction of travel from the heel
during foot contact to the contralateral heel during the next
foot contact.
Step time: duration from foot contact to contralateral
foot contact.
Step velocity: step length divided by step time.
Stance time: duration from foot contact to when the foot is
lifted off the ground.
Swing time: duration from when the foot is lifted off the
ground to its next contact with the ground.
Step width: the perpendicular distance between the heel
during foot contact and the direction of travel of the
contralateral foot.
The mean, variability, and asymmetry of gait characteristics
were calculated as follows:
Mean: the mean of left and right steps were calculated
separately before calculating the (overall) mean of the left and
right steps.
Variability: the variance of the left and right steps were
calculated separately before calculating the overall variability
as the square root of the average (of left and right) variance,
resulting in a combined standard deviation.
Asymmetry: the mean of left and right steps were
calculated separately before calculating the absolute (non-
directional) difference between the means of left and
right steps.
Clinical Assessments
Details of the clinical assessments have been described previously
(Khoo et al., 2013; Yarnall et al., 2014). Briefly, age, sex,
height, mass, and depression [Geriatric Depression Scale (GDS-
15)] were recorded. The National Adult Reading Test (NART)
assessed premorbid intelligence at baseline. Global cognition was
assessed through the Montreal Cognitive Assessment (MoCA)
as well as the Mini-Mental State Examination (MMSE). The
five times sit-to-stand test was used as a surrogate marker
of strength, and confidence in balance during activities of
daily living was measured with the Activities-specific Balance
Confidence (ABC) scale and the time participants were able
to stand on one leg (mean of left and right; capped at 30 s).
PD specific motor severity was measured using the Movement
Disorders Society Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS III) from which the Hoehn and Yahr Stage
(H&Y) was assessed. The presence of freezing of gait (FOG)
was assessed with the FOG questionnaire. Levodopa equivalent
daily dose (LEDD) was calculated at each assessment (Tomlinson
et al., 2010). The anticholinergic burden was assessed using
the Anticholinergic Drug Scale (ADS), where each medication
was classified on a scale from 0 to 3 according to no (0),
mild (1), moderate (2), or high (3) anticholinergic activity
(Carnahan et al., 2006). Medications not specified on the
ADS were reviewed according to the literature to ensure
accurate scoring.
Statistical Analysis
The analysis was completed using SPSS (IBM Corp. V.24,
USA) and R (R Foundation for Statistical Computing, V3.5.2,
Austria). First, univariate analyses described demographic,
clinical, and gait data for both groups at baseline assessment,
through Student’s t-test, Mann–WhitneyU, and Chi-square tests
as appropriate. The distributions of continuous variables were
assessed through the Skewness–Kurtosis test and inspection
of boxplots and histograms. Due to high levels of skewness,
gait asymmetry data were square-root transformed and
temporal variability data were natural log-transformed for
cross-sectional analysis; no outliers were removed. Within-
group baseline differences between participants who did
and did not complete the 72-month gait assessment were
also assessed.
Second, linear mixed-effects models (LMEM; R, ‘‘lme4’’ and
‘‘lmerTest’’) modeled change in each gait characteristic, as these
can give appropriate estimates of regression coefficients despite
significant participant drop-out across the study period (Little,
1995; Figure 1). Random slope models gave each participant a
unique intercept and slope, accounting for individual variability
and allowing for correlation between intercept and slope. Even
though it is possible to calculate change scores for participants
with only one assessment using LMEM, we chose to include
only participants who were assessed at least twice to ensure
more robust estimates of change in gait. Baseline age and sex
were included as fixed effects in all models. Likelihood ratio
tests assessed model fit. We performed a preliminary analysis
to check for a non-linear change of gait by comparing the
fit of a linear model and a model with an added a quadratic
term of time for each gait characteristic. The two models were
compared using likelihood ratio tests with a X2 distribution.
This analysis indicated there was little evidence (p > 0.05)
that the quadratic term improved the model fit for any gait
characteristic and so a model of linear change over time
was used.
There were three stages to longitudinal analyses
addressing each of our aims in turn: (i) to quantify the
progression of gait impairment over time, basic models
independently assessed changes in gait for PD and control
groups; (ii), to compare the rate of gait change between
the groups, models included the interaction between
group and time (Group × Time); and (iii) to evaluate the
association between change in gait and change in LEDD, PD
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TABLE 1 | Baseline demographic characteristics.
Characteristic Control (n = 130) PD (n = 109) Group difference (test statistic, p)
Age (years) 69.5 (7.4) 67.4 (9.9) t = 1.87, p = 0.063
Sex 55% f (72 f, 58 m) 34% f (37 f, 72 m) χ2 = 10.99, p = 0.001*
Height (m) 1.68 (0.10) 1.70 (0.08) t = −1.05, p = 0.294
Body mass (kg) 78.3 (14.9) 78.8 (15.4) t = −0.28, p = 0.782
GDS-15 1.3 (2.0) 2.6 (2.2) U = 4,077, p < 0.001*
Education (years) 14 (4) 13 (4) U = 3,723, p = 0.373
NART 117 (8) 115 (11) U = 6,650, p = 0.483
MoCA` 27 (2) 25 (4) U = 2,601, p ≤ 0.001*
MMSE 29 (1) 29 (1) U = 5,047, p ≤ 0.001*
Sit to stand (s) 12.1 (3.4) 14.1 (4.7) U = 4,841, p ≤ 0.001*
Single leg stance (s) 16.2 (11.4) 13.8 (10.8) U = 6,382, p = 0.185
ABC (0-100) 92.7 (9.5) 82.2 (19.5) U = 4,880, p ≤ 0.001*
MDS-UPDRS III (0–132) - 25.0 (10.3) -
H&Y stage n (%) - I 26 (23.9%); II 65 (59.6%); III 18 (16.5%) -
n (%) who report FOG - 11 (10.1%) -
LEDD (mg/day) - 175 (132) -
ADS (total summed score) - 0.7 (1.3) -
Notes: BMI, Body Mass Index; GDS-15, Geriatric Depression Scale; NART, National Adult Reading Test; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination;
ABC, Activities-specific Balance Confidence; MDS-UPDRS III, Movement Disorders Society Unified Parkinson’s Disease Rating Scale; H&Y, Hoehn& Yahr; FOG, Freezing of Gait; LEDD,
Levodopa Equivalent Daily Dose; ADS, Anticholinergic Drug Scale. ` indicates a smaller sample size; - indicates PD specific metrics not collected for control participants; control n = 73,
PD n = 104. *p < 0.05.
models included the interaction between LEDD and time
(LEDD× Time).
To aid data interpretation concerning our study aims,
significant gait changes in the PD cohort that were related
to aging and disease progression were discerned using the
following criteria:
(1) Gait-change related only to disease progression: a significant
gait change was identified in the PD cohort but not in
controls, where the rate of change differed significantly
between groups.
(2) Gait change related to aging: a significant gait change was
identified in both PD and control cohorts, where the rate of
change did not differ significantly between PD and control
groups.
(3) Gait change related to both aging and disease progression:
a significant gait change in both PD and control
cohorts, where the rate of change differed significantly
between groups.
Also, individual trajectories of gait change over time were
plotted to illustrate variability within the cohorts. We used
a threshold of p < 0.05 to guide statistical interpretation. p-
values were not adjusted for multiple comparisons. This allowed
direct comparisons with our previous analysis quantifying gait
change over the first 3 years of PD (Rochester et al., 2017) and
also reduced the risk of type II error. As multiple comparisons
increase the risk of type I statistical error, we present full p-values
for the reader to assess the statistical robustness of our findings.
RESULTS
Study Participants and Baseline
Assessments
One-hundred and thirty control and 109 PD participants
completed at least two assessments, so were included in
this analysis (Supplementary Table 1). At baseline, PD
participants had similar age, height, mass, and NART scores
to controls (Table 1). The PD group had proportionately
more males, poorer global cognition (MoCA and MMSE),
lower mood (GDS-15), poorer balance confidence (ABC),
and were slower performing the sit-to-stand test (p ≤
0.001). The mean time to baseline assessment from PD
diagnosis was 6 months, and from the first subjective motor
symptom was 27 months. Motor score severity at baseline
was low (mean MDS-UPDRS III = 25); 10% had already
experienced FOG and most (90%) were taking dopaminergic
medication, in keeping with clinical practice. Thirty-one
percent of people with PD were taking medication with
an anticholinergic burden although the overall burden was
low, with a mean score of 0.7, which may reflect increased
clinician awareness of the adverse outcomes associated
with anticholinergic in PD. For both groups, participants
who completed the 72-month assessment (‘‘completers’’)
were younger and had better baseline performance on
the MoCA compared to ‘‘non-completers’’ who did not
attend a 72-month assessment (Supplementary Table 2).
Additionally, PD completers had better balance (higher ABC
and single leg stand time) and less severe motor disease
(lower MDS-UPDRS III and H&Y stage) at baseline than
non-completers.
Baseline gait characteristics for PD and control groups
have previously been detailed (Galna et al., 2015; Rochester
et al., 2017). Briefly, 13 of 16 characteristics differed between
the groups (Supplementary Table 3); PD participants
walked slower with a shorter step length, longer step and
stance time, and greater asymmetry and variability (except
for less step width variability) compared to controls.
PD completers walked significantly faster with a longer
step at baseline compared to non-completers. Control
completers were significantly less variable in stance-time,
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step velocity, and step length than non-completers
(Supplementary Table 4).
Progression of Gait Impairment Over
72 Months
In both groups, gait characteristics from all five domains
significantly progressed over 72 months. Progression was more
extensive in the PD cohort. In basic change models, ten of
sixteen characteristics significantly changed in PD compared
to seven characteristics in controls (Table 2, Supplementary
Figure 1). In PD, gait became significantly slower, with a
shorter step length, greater variability (swing and step time, step
length, step width), reduced asymmetry (swing time), wider step
width, and faster steps (step and swing time). Gait also became
significantly slower in controls, with shorter steps, greater
variability (step length), greater asymmetry (step length), wider
step width, and faster swing time. Variation was considerable
between individuals in the trajectories of change for each gait
characteristic (Figure 2). The overall severity of PD-related
motor symptoms also worsened as shown by a 3.0 point increase
per year in the UPDRS III (CI95% 2.51, 3.61, p< 0.001).
Discerning PD-Specific Gait Changes
From Aging
In line with the second study aim, the ten significant gait
changes identified within the PD cohort have been separated
into those relating to aging and/or disease progression, according
to three criteria outlined in the methods. Four characteristics
demonstrated change-related only to disease progression,
meeting criterion 1. Specifically, increasing variability (step and
swing time), reducing asymmetry (swing time), and worsening
postural control of gait (increasing step width variability) were
significant changes in PD but not controls (Figure 2A), and
change differed significantly between the groups (significant
Group× Time interaction, Table 2, Figure 3).
Three characteristics changed solely due to aging, meeting
criteria 2: slowing step velocity, quickening swing time, and
increasing step width were exhibited in PD and controls at
similar rates. Step time changed in the PD group only, but does
not meet any outlined criteria so has not been considered further.
Finally, two characteristics demonstrated change related
to both aging and disease progression, meeting criteria 3.
Step length shortened and step length variability increased
significantly in both groups; however, the rate of change was
significantly greater in PD than controls (Figure 2B).
Associations Between Gait Changes and
Change in Levodopa Dose Over Time
LEDD increased by 106 mg/day each year. Ninety-three percent
of people with PD had increased LEDD compared to baseline
assessment (two had a decreased dosage, six remained at
baseline dosage). Only one gait characteristic was related to
LEDD change; larger increases in step width variability related
to greater increases in LEDD over time (Table 2). Inclusion
of the LEDD × Time interaction resulted in no significant
change in step width variability (p > 0.05), indicating that
step width variability change is at least partially explained by a
change in LEDD. All other gait characteristics meeting criteria
1 and 3 did not show associations between gait change and
LEDD change and therefore exhibited disease-specific change
that was not related to levodopa adjustments (Figure 3,
Supplementary Figure 1).
DISCUSSION
This is the first study to objectively and quantitatively model
progression of gait impairment over 6 years in an incident
cohort of PD compared to a well-matched control group.
This demonstrated changes associated primarily with aging
rather than PD progression, and also those characteristics
due to aging which are accelerated by the presence of PD.
In people with PD, we identified four gait characteristics
that showed disease-specific progression, three that showed
age-related progression, and two that could be explained
through a combination of age and disease-specific change. Most
gait changes occurred irrespective of increasing dopaminergic
medication, highlighting limitations of dopaminergic therapies,
and indicating the involvement of other mechanisms of gait
impairment. The broad lack of correlation between increases
in levodopa and gait decline indicates a significant variation in
how gait impairments respond to dopaminergic therapy between
people with PD. Novel therapies targeting non-dopaminergic
mechanisms are therefore required to slow the progression of
gait progression and reduce the associated consequences of falls
and reduced activity. Ultimately, these findings improve the
current understanding of mechanisms of gait impairment in
early PD.
Changes in Gait Over 6 Years
Our first aim was to describe gait changes in PD and controls
over an extended period of 6 years. As expected, many gait
characteristics changed in both PD and control cohorts; changes
in gait occurredmore frequently and at greater magnitudes in PD
compared to changes in controls. Several changes were unique to
each cohort, highlighting the specificity of gait change.
PD-Specific Changes in Gait
To fulfill our second aim, three criteria established gait changes
specific to PD pathology (criteria 1), reflective of aging (criterion
2), or indicative of a combination of PD progression and aging
(criteria 3). Four characteristics significantly changed in PD
only (increased variability of swing time, step time and step
width, and reduced swing time asymmetry) and describe changes
specifically due to disease progression. These findings extend
previous work in this cohort over shorter periods (Galna et al.,
2015; Rochester et al., 2017; Hobert et al., 2019) by revealing
additional changes in asymmetry and variability that are not
evident over 18 or 36 months. Our findings are also supported by
a smaller study that showed step time variability increased more
over 5 years in 22 people in the early stages of PD compared
to a typically aging cohort (Hobert et al., 2019). We were not
able to confirm the specific disease mechanisms underlying
changes in variability (step, swing, step width) in this study.
However, evidence suggests that increasing variability may be
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TABLE 2 | Modeled change in gait characteristics over 72-months for control and Parkinson’s disease (PD) participants.
Controls PD Group × Time interaction LEDD × Time interaction
∆ per
year
p 95% CI ∆ per year p 95% CI β P 95% CI β p 95% CI
Pace
Step velocity (m/s) −0.0053 0.046∗ −0.0105, −0.0002 −0.0124 0.004∗ −0.0208, −0.0042 −0.0068 0.158 −0.0163, 0.0026 7.4 × e−6 0.415 −10.4 × e−6, 25.2 × e−6
Step length (m) −0.0047 <0.001∗ −0.0068, −0.0026 −0.0092 <0.001∗ −0.0131, −0.0054 −0.0044 0.035∗ −0.0085, −0.0003 −0.7 × e−6 0.855 −7.7 × e−6, 6.4 × e−6
Swing time sd (ms) 0.0113 0.893 −0.1583, 0.1767 0.3968 0.016∗ 0.0752, 0.7239 0.3755 0.031∗ 0.0345, 0.7187 −0.6 × e−3 0.301 −1.7 × e−3, 0.5 × e−3
Variability
Step time sd (ms) −0.0265 0.773 −0.2066, 0.1559 0.5131 0.007∗ 0.1491, 0.8958 0.5198 0.009∗ 0.1320, 0.9129 −0.3 × e−3 0.535 −1.4 × e−3, 0.7 × e−3
Stance time sd (ms) −0.0041 0.976 −0.2699, 0.2620 0.4574 0.061 −0.0199, 0.9461 0.4826 0.075 −0.0486, 1.0187 −0.9 × e−3 0.283 −2.4 × e−3, 0.7 × e−3
Step velocity sd
(m/s)
−0.0001 0.708 −0.0006, 0.0004 0.0007 0.107 −0.0001, 0.0016 0.0009 0.060 −0.00003, 0.0019 0.01 × e−6 0.993 −2.6 × e−6, 2.6 × e−6
Step length sd (m) 0.0003 0.002∗ 0.0001, 0.0005 0.0009 <0.001∗ 0.0005, 0.0013 0.0006 0.004∗ 0.0002, 0.0010 −0.2 × e−6 0.759 −1.4 × e−6, 1.1 × e−6
Rhythm
Step time (ms) −0.9841 0.160 −2.369, 0.3882 −1.789 0.007 −3.049, −0.529 −0.8069 0.353 −2.503, 0.8897 −2.1 × e−3 0.363 −6.6 × e−3, 2.5 × e−3
Swing time (ms) −0.9276 0.006∗ −1.579, −0.287 −2.039 <0.001∗ −3.095, −0.992 −1.1013 0.068 −2.2846, 0.0831 −0.7 × e−3 0.669 −4.3 × e−3, 2.8 × e−3
Stance time (ms) −0.9378 0.418 −3.231, 1.342 −1.385 0.183 −3.418, 0.694 −0.3487 0.806 −3.131, 2.462 −4.0 × e−3 0.235 −10.7 × e−3, 2.7 × e−3
Asymmetry
Step time asy (ms) 0.4435 0.020∗ 0.0731, 0.8213 −0.6508 0.239 −1.736, 0.451 −1.0796 0.054 −2.176, 0.0238 −0.8 × e−3 0.556 −3.7 × e−3, 2.0 × e−3
Swing time asy (ms) 0.2557 0.069 −0.0202, 0.5304 −0.8137 0.042∗ −1.594, −0.027 −1.0142 0.012∗ −1.803, −0.2214 −0.4 × e−3 0.704 −2.4 × e−3, 1.6 × e−3
Stance time asy
(ms)
0.2213 0.145 −0.0786, 0.5190 −0.7502 0.052 −1.505, 0.011 −0.8782 0.027∗ −1.653, −0.0997 −0.6 × e−3 0.564 −2.6 × e−3, 1.5 × e−3
ostural Control
Step length asy (m) 0.0008 0.025∗ −0.0001, −0.0014 0.0009 0.125 −0.0002, −0.0020 0.0002 0.813 −0.0011, 0.0014 0.1 × e−6 0.959 −3.0 × e−6, 3.1 × e−6
Step width (m) 0.0007 0.027∗ 0.0001, 0.0013 0.0009 0.014∗ 0.0002, 0.0017 0.0002 0.650 −0.0007, 0.0012 0.6 × e−6 0.632 −1.8 × e−6, 2.9 × e−6
Step width sd (m) −0.0001 0.290 −0.0003, 0.0001 0.0008 <0.001∗ 0.0004, 0.0012 0.0009 <0.001∗ 0.0005, 0.0013 1.6 × e−6 <0.001∗ 0.7 × e−6, 2.5 × e−6
Notes All models were adjusted for baseline age and sex. asy, asymmetry; sd, standard deviation (gait variability). *p < 0.05.
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FIGURE 2 | Change in gait over 6 years for control and Parkinson’s disease (PD) participants for gait characteristics that demonstrated a significant change in PD
related to disease progression. Panel (A) shows gait characteristics that significantly changed in PD but not controls so demonstrated change related to disease
progression only. Panel (B) shows gait characteristics that significantly changed in PD and control groups, but the rate of change was greater in PD, so
demonstrated change related to both aging and disease progression. Bold lines show overall change within each group; faint lines show change for individuals.
due to aggregation of disease pathologies over the first 6 years of
PD affecting the neural control of gait, including amyloid and tau
(Kang et al., 2013; Rochester et al., 2017). Whilst these analyses
using cerebrospinal fluid (CSF) markers cannot inform us of the
specific neural regions where pathological aggregates may most
affect gait variability, assessments of amyloid with gait speed
indicate that greater pathological burden within basal ganglia
regions, the temporal cortex, and the anterior cingulate may be
associated with worse gait performance in healthy older adults
(Del Campo et al., 2016; Nadkarni et al., 2017; Wennberg et al.,
2017). Neurological changes exacerbated by PDmay additionally
influence changes in gait variability (Wilson et al., 2019). Greater
gait asymmetry in people with PD at baseline is in agreement
with an asymmetrical pattern of neuronal loss (Wang et al., 2015;
Claassen et al., 2016). Moreover, reduced asymmetry over time
in PD likely relates to bilateral neuronal loss with PD progression
(Rousseaux et al., 2012). Further work is needed to define these
mechanisms more clearly.
The Role of Levodopa in PD Gait
Progression
To further understand the drivers of gait progression specific
to PD, we explored the relationship between change in gait
and change in levodopa, addressing our third aim. This study,
along with previous work (Rochester et al., 2017), demonstrated
that increasing step width variability is related to increasing
levodopa medication. The reasons for this are unclear and
the increase in step width variability in response to levodopa
medication can be interpreted in different ways. Speculatively,
increased levodopa may allow for more precise control of
mediolateral foot placement. In contrast, a more variable
step width may be a compensation for balance difficulties
aggravated by increased levodopa dosage (Curtze et al., 2015).
It is also possible that changes in levodopa and step width
variability both reflect a more progressive PD phenotype
and are not causally linked. No other gait characteristics
were related to levodopa change. Dopaminergic medication
may therefore mitigate the pathophysiological progression of
gait impairment to an insufficient extent, or the progression
of discrete gait impairments may be resistant to levodopa
medication (dopa-resistant). Also, dopaminergic medications
are most commonly used to treat motor symptoms in PD
yet their extended use may have a negative effect on gait.
Whilst the severity of freezing of gait (FOG) is thought to
lessen with dopaminergic medications, it has been reported
that FOG may be less prevalent in those not treated with
levodopa (Garcia-Ruiz, 2011; Koehler et al., 2019; Nonnekes
et al., 2020). Additionally, the use of dopamine agonists, which
augment the effects of levodopa, may lead to an increased risk
of falling or induce FOG (Serrao et al., 2015). Furthermore,
the effects of dopaminergic medications lessen with disease
progression (Jenner, 2015) and long-term use of dopaminergic
therapies typically leads to involuntary movements known
as dyskinesia (Iravani and Jenner, 2011). Changes in gait
reported in this study may have therefore been augmented
by continued levodopa usage; to understand this further,
gait progression could be monitored in levodopa-naïve
PD participants in the future and compared to findings
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FIGURE 3 | Radar plot illustrating the relative change in each gait characteristic over 72-months. The central dotted line represents no change. Deviations from zero
along the axes radiating from the center of the plot represent the relative change in each gait characteristic over 72-months within each diagnostic group, calculated
as the modeled change per year divided by the standard deviation of the modeled change. Gait characteristics are abbreviated as follows: SV, step velocity; SL, step
length; Swi, swing time; ST, Step time; Sta, Stance time; Wid, Step width; sd, standard deviation (gait variability); asy, asymmetry. † indicates a significant change in
gait in the PD cohort over 72 months; ‡ indicates a significant change in gait in controls over 72 months; ∗ indicates a significantly different rate of change in PD gait
compared to the rate of gait change in controls. †∗Denotes criteria 1 satisfied; †‡denotes criteria 2 satisfied; †‡∗denotes criteria 3 satisfied.
presented here. These challenges highlight the need for
novel non-dopaminergic therapies (Curtze et al., 2015;
Galna et al., 2015).
Although the precise mechanisms of non-dopaminergic gait
control are unclear, emerging evidence suggests the importance
of the cholinergic system (Morris et al., 2019). Cholinergic
neurons in the pedunculopontine nucleus (PPN) influence
gait and postural control (Karachi et al., 2010), and slower
walking speed in PD is associated with increases in short-
latency afferent inhibition (Rochester et al., 2012) and cholinergic
denervation (Bohnen et al., 2013; Müller et al., 2015). Also,
deep brain stimulation (DBS) within the PPN may improve step
velocity (Thevathasan et al., 2012); suggesting interventions that
target brain regions not primarily dependent on dopamine may
therefore help to mitigate gait impairment in PD. The benefits of
drugs targeting the cholinergic system on PD gait are also being
explored (Henderson et al., 2016; Smulders et al., 2016; Müller
et al., 2019). Overall, interpretation of the relationship between
dopamine and gait progression is limited as gait was not assessed
‘‘off’’ medication, nor were biomarkers of dopaminergic activity
such as DAT imaging used. Nevertheless, our findings indicate
that discrete gait characteristics progress irrespective of levodopa,
suggesting the importance of non-dopaminergic mechanisms in
gait impairment.
The Contribution of Aging to PD Gait
Progression
Understanding how gait changes with normal aging is
important as age-related changes cumulatively contribute to gait
progression in people with PD alongside disease progression.
Three characteristics changed in both PD and control cohorts
over 6 years; the change was therefore considered to be due
primarily to aging mechanisms rather than disease progression.
These changes (slowing of gait, widening of steps, and quickening
swing time) met criteria 2.
Slowing of gait is considered a typical feature of PD
progression. In this study, the walking speed of people with
PD slowed by 1.24 cm/s per year (CI95%: 0.4 to 2.1 cm/s
per year). This is not as severe a decline as reported by
either Ellis et al. (2016; 4 cm/s per year) or Hobert et al.
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(2016; 3.4 cm/s per year) in early PD, yet faster than the
4.3 cm/s per year increase in walking speed during a 6-min walk
reported by Cavanaugh et al. (2012). Differences in demographic
characteristics, disease severity and duration, testing setting and
paradigm, and treatment regime may all help explain differences
in the mean estimate of change between these studies. Moreover,
each of these studies reported a large variation in change
over time between participants, indicating that gait impairment
evolves differently for each individual with PD, warranting
much-needed research for prognostic markers of gait decline
in PD to better inform personalized treatment. Interestingly,
we also found that walking speed (step velocity) slowed over
time in both groups, suggesting this is a more general feature
of aging. Although the rate of change was greater in PD this
was not significant, replicating previous findings (Galna et al.,
2015; Hobert et al., 2019). While walking speed may be a useful
measure of change and response to therapy, interpreting change
in walking speed is more complex and we posit are more likely
to reflect a combination of aging and disease. This may explain,
in part, the large inter-individual variation in rates of gait change
within each group. Walking speed provides an overall measure
of gait performance, influenced by discrete characteristics such
as step length, timings of steps, and step width (Wade, 1992;
Galna et al., 2015). Further investigation into predictive factors
for gait change in PD and healthy aging cohorts may give better
insight into the reasons behind individual differences in gait
progression and aid better interpretation of reduced gait speed
in PD and aging cohorts. Small yet clinically meaningful changes
in gait speed are reported as 3-6 cm/s in older adults with
mobility issues (Perera et al., 2006) and in PD (Hass et al.,
2014). Our work, therefore, indicates that a clinically meaningful
change in gait typically occurs within the first 6 years of PD
(7.4 cm/s over 6 years in people with PD; see Table 2 for
estimates of yearly change). Overall, given that change in step
velocity does not significantly differ between PD and control
groups, looking beyond walking speed is important in order
to allow more nuanced interpretation of changes and their
underlying mechanisms.
Age-related change contributes to gait impairments observed
in PD, suggesting that therapies addressing features of aging
may be effective in reducing the burden of PD. It is important,
therefore, to consider the mechanisms driving age-related gait
change. Change may be due to atrophy and loss of muscle
strength (Abernethy, 2005; Song and Geyer, 2018), physical
inactivity (Busch et al., 2015), and development of age-related
conditions, such as osteoarthritis (Zhang and Jordan, 2010)
causing increased pain and stiffness during movement (Jayakody
et al., 2018). Age-related changes in the brain such as atrophy
and white matter abnormalities also explain the slowing and
increased variability of gait during aging (Wilson et al., 2019).
Increasing evidence implies that specific neural regions or
networks underpin discrete gait characteristics (Tian et al.,
2017), which could be specifically targeted to prevent discrete
components of age-related gait decline. On this point, gait
performance in PD is improved by exercise-based interventions
aiming to increasemuscle strength and activity (van der Kolk and
King, 2013; Shen et al., 2016); speculatively these therapies may,
at least partially, be targeting age-related changes which in turn
positively impact PD gait.
Two gait characteristics, step length, and step length
variability, significantly worsened within PD and control groups
over 6 years and specifically, those changes occurred more
rapidly in PD. These characteristics met criteria 3, suggesting
that both PD and age-related mechanisms contributed to their
progression. In previous work over a shorter time frame
[36 months from diagnosis (Rochester et al., 2017)] step length
change was not significantly different in PD compared to
controls. This may be due to shorter step length in PD strongly
associating with dopaminergic dysfunction (Galna et al., 2015)
and the resultant hypokinesia (Morris et al., 1996), somay decline
as dopaminergic medications become less effective over time due
to neuronal cell loss (Zahoor et al., 2018). Alternatively, change
may simply be due to loss of muscle mass and strength over time
(sarcopenia), as a result of aging or as a secondary consequence
of the reduced activity observed during PD. Further investigation
into the underlying mechanisms of these gait changes such as
direct measurement of muscle mass over time may indicate
whether these are purely age-related changes accelerated by
disease progression, or whether aging and disease mechanisms
act independently of each other to cause change. Collectively,
our findings highlight the benefits of longer follow-up duration,
through identifying changes related specifically to disease
progression and changes reflective of both disease progression
and aging over 6 years. These gait characteristics may act as new
therapeutic targets for the prevention of gait progression in PD.
Study Strengths and Limitations
This study is the largest to document gait change in PD over
the longest period from diagnosis, in a relatively homogeneous
cohort of incident PD participants. The main strength was that
gait changes due to aging and disease progression could be
parsed, as a well-matched control cohort was assessed alongside
people with PD. Relatively precise modeling of gait change in
early PD was achieved as PD participants were recruited close
to diagnosis, enabling monitoring over the first 6 years of the
disease. Inter-individual variation was accounted for through
the random effect term included in all models. The inclusion
of LEDD in analyses enabled the investigation of gait changes
that were related and, arguably, more importantly, not related
to changes in dopaminergic medication, to identify potential
therapeutic targets for non-dopaminergic interventions. The
effects of dopamine on gait progression could be further explored
by comparing gait progression for characteristics measured
‘‘on’’ and ‘‘off’’ medication. Specifically, testing participants
both on and off medication will allow us to better understand
the progression of the underlying disease as well as explore
the complex relationship between step width variability and
dopaminergic medication.
Some limitations should be noted. As with many longitudinal
studies, attrition was substantial (57%) although comparable
to similar studies. PD completers were younger, with a less
severe motor disease, better global cognition, and less severe gait
impairment at baseline, indicating a potential underestimation
of overall progression rates. Mixed-effects modeling allowed the
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use of all data, reducing bias compared to traditional analytical
approaches. PDmisdiagnosis is unlikely to have affected findings
as the diagnosis was reviewed at each assessment and the number
of revised diagnoses was low (Figure 1). We chose not to correct
for multiple comparisons; this was justified as it allowed for
direct comparison with gait changes over 36 months (Rochester
et al., 2017), and reduced the risk of type II error. To account
for the possibility of type I errors, we have been cautious in our
interpretation of the findings and also provided p-values for each
comparison for transparency. Finally, it was beyond the scope of
the aims of this article to examine underlying non-dopaminergic
and cognitive mechanisms of gait decline in people with PD,
however, these remain pertinent topics for future research.
CONCLUSIONS
Discrete gait impairments progress over 6 years after a
diagnosis of PD, due to a combination of disease-specific and
age-related mechanisms. Gait changes were mostly unrelated to
dopaminergic medication adjustments, highlighting limitations
of current dopaminergic therapy and the need to improve
interventions targeting gait decline in PD.
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